-
Product Insights
NewStreptococcal Pneumonia – Drugs In Development, 2024
Empower your strategies with our Streptococcal Pneumonia – Drugs In Development, 2024 report and make more profitable business decisions. Streptococcus pneumoniae, or pneumococcus, is a Gram-positive spherical bacteria, and alpha-hemolytic member of the genus Streptococcus. Pneumococcal infections are present throughout the world and are most common during the winter and early spring months. Pneumoniae is prevalent in large part due to its colonizing ability in the nasopharynx. Almost 40-50% healthy children and 20-30% of healthy adults are carriers. With childhood conjugate...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EP-547 in Hepatitis B
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. EP-547 in Hepatitis B Drug Details: EP-547 is under developmant for the treatment of cholestatic pruritus...
-
Product Insights
NewNet Present Value Model: X4 Pharmaceuticals Inc’s Mavorixafor
Empower your strategies with our Net Present Value Model: X4 Pharmaceuticals Inc's Mavorixafor report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Merck & Co Inc’s Cavatak
Empower your strategies with our Net Present Value Model: Merck Co Inc's Cavatak report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Mavorixafor in Neutropenia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Mavorixafor in Neutropenia Drug Details: Mavorixafor (X4P-001) is under development for the treatment of severe...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EP-547 in Pruritus
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.EP-547 in Pruritus Drug Details:EP-547 is under developmant for the treatment of cholestatic pruritus due to primary...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VP-301 in Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VP-301 in Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.VP-301 in Lymphoma Drug Details: VP-301 is under development for the treatment of relapsed...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SD-101 in Hepatocellular Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SD-101 in Hepatocellular Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SD-101 in Hepatocellular Carcinoma Drug Details: SD-101 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BCA-101 in Laryngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BCA-101 in Laryngeal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BCA-101 in Laryngeal Cancer Drug Details: BCA-101 is under development for the...
-
Company Profile
X4 Pharmaceuticals Inc – Company Profile
X4 Pharmaceuticals Inc, formerly Arsanis Inc, is a clinical-stage biopharmaceutical company, that develops oral, small molecule therapeutics to treat cancer and rare diseases. The company’s pipeline products include Mavorixafor, an allosteric inhibitor of CXCR4 for the treatment of warts, hypogammaglobulinemia, immunodeficiency and myelokathexis (WHIM) syndrome X4P-002 and X4P-003, small molecule antagonists of chemokine receptor CXCR4 for treating glioblastoma multiforme and primary immune deficiencies (PI's). The company is developing oral allosteric antagonists of CXCR4 in order to block overstimulation of the...
Add to Basket